预测mCRPC激素治疗与化疗获益的基因组生物标志物
本研究基于美国去标识化临床基因组数据库的回顾性队列,评估常见基因组变异对转移性去势抵抗性前列腺癌(mCRPC)患者接受新型激素治疗(NHT)与紫杉烷化疗的预测关联。主要队列包括308例患者的180个NHT和179个紫杉烷治疗线,结果显示AR扩增(ARamp)、PTEN变异(PTENalt)或RB1变异(RB1alt)患者中NHT相对紫杉烷的PSA应答、至下一治疗时间(TTNT)和总生存(OS)更差。ARamp状态是预测NHT相对紫杉烷疗效不佳的候选生物标志物。
要点
- ARamp、PTENalt或RB1alt患者中NHT相对紫杉烷的TTNT和OS更差
- ARamp患者中NHT相对紫杉烷的PSA应答更差
- ARamp状态可预测mCRPC中NHT相对紫杉烷疗效不佳
核心结论
- ARamp状态是预测mCRPC患者NHT相对紫杉烷疗效不佳的候选生物标志物。
研究设计与样本
- 回顾性队列研究,使用2011至2020年美国去标识化临床基因组数据库。
- 主要队列包括308例患者的180个NHT和179个紫杉烷治疗线。
- 序贯队列包括55例患者中NHT后立即接受紫杉烷的治疗线。
主要发现
- ARamp或PTENalt患者中NHT相对紫杉烷的PSA应答更差。
- ARamp、PTENalt或RB1alt患者中NHT相对紫杉烷的TTNT和OS更差。
- 序贯队列中仅ARamp与后续紫杉烷获益增加一致相关。
临床怎么用
- 在mCRPC患者考虑NHT与紫杉烷两种选择时,可检测ARamp状态以辅助治疗决策。
局限性
- 研究为回顾性设计,可能受治疗分配偏倚影响,虽采用IPTW调整。
- 序贯队列中RB1alt患者极少,无法评估其关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biomarkers predicting second-generation novel hormonal therapy (NHT) benefit relative to taxanes are critical for optimized treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) patients. These associations have not been reported simultaneously for common mCRPC genomic biomarkers. OBJECTIVE: To evaluate predictive associations of common genomic aberrations in mCRPC using an established comprehensive genomic profiling (CGP) system. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study used data from a deidentified US-based clinicogenomic database comprising patients treated in routine clinical practice between 2011 and 2020, evaluated with Foundation Medicine CGP in tissue biopsies obtained around the time of treatment decision. The main cohort included 180 NHT and 179 taxane lines of therapy (LOTs) from 308 unique patients. The sequential cohort comprised a subset of the main cohort NHT LOTs immediately followed by taxane from 55 unique patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prostate-specific antigen (PSA) response, time to next treatment (TTNT), and overall survival (OS) were assessed. Main cohort analyses were adjusted for known treatment assignment biases via inverse probability of treatment weighting (IPTW) in treatment interaction models. RESULTS AND LIMITATIONS: In the main cohort, patients with AR amplification (ARamp) or PTEN aberrations (PTENalt) had worse relative PSA response on NHT versus taxanes compared with patients without. Patients with ARamp, PTENalt, or RB1 aberrations (RB1alt) also had worse relative TTNT and OS on NHT but not on taxanes. In multivariable models for TTNT and OS adjusted via IPTW, ARamp, PTENalt, and RB1alt were shown as poor prognostic factors overall and demonstrated significant treatment interactions, indicating reduced hazards of therapy switch and death on taxanes versus NHT. Consistent associations favoring increased benefit from subsequent taxane despite prior NHT treatment line were observed only for ARamp in the sequential cohort, in which very few patients had RB1alt for assessment. CONCLUSIONS: ARamp status is a candidate biomarker to predict poor effectiveness of NHT relative to taxanes in mCRPC in scenarios where both options are considered. PATIENT SUMMARY: Specific alterations in the DNA of tumors may assist in choosing between novel oral hormonal therapies and standard chemotherapy in advanced prostate cancer patients.
引用
- Graf RP, Fisher V, Mateo J, et al. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2021. PMID: 34716049. doi:10.1016/j.eururo.2021.09.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。